Trial Profile

An Open Label Phase I PET Imaging Study to Investigate the Bio-distribution and Tumor Uptake of [89Zr]Zr-BI 765063 and [89Zr]Zr-BI 770371 in Patients With Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer or Melanoma Who Are Treated With Ezabenlimab

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs BI 765063 (Primary) ; Ezabenlimab (Primary)
Indications Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Squamous cell cancer
Focus Pharmacokinetics
Sponsors Boehringer Ingelheim

27 May 2026 Planned End Date changed from 28 Aug 2026 to 16 Sep 2026.
27 May 2026 Planned primary completion date changed from 29 May 2026 to 16 Sep 2026.
12 May 2026 Planned End Date changed from 6 Aug 2026 to 28 Aug 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com